HC Wainwright & Co. Reiterates Buy on Lexaria Bioscience, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Lexaria Bioscience (NASDAQ:LEXX) and maintained a $10 price target.
July 18, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Lexaria Bioscience and maintained a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100